P-225Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. (2nd July 2019) - Javle, M; Borbath, I; Clarke, S; Hitre, E; Louvet, C; Macarulla, T; Oh, D; Spratlin, J; Valle, J; Weiss, K; Berman, C; Howland, M; et al.